MAPT and Alzheimer disease: While many exploratory biomarkers have been proposed for AD, cerebrospinal fluid levels of tau and Aβ levels, together with imaging studies (such as positron emission tomography carbon 11-labeled Pittsburgh compound B), are the most widely accepted [19].